Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

pan-KRAS inhibitor PF-07985045

An orally bioavailable inhibitor of KRAS mutations, with potential antineoplastic activity. Upon oral administration, pan-KRAS inhibitor PF-07985045 targets, binds to and inhibits various forms of KRAS mutations, thereby inhibiting KRAS-dependent signaling. This inhibits the proliferation of and induces apoptosis in tumor cells in which KRAS is mutated. KRAS plays an important role in cell signaling, division and differentiation. Mutations of KRAS may induce constitutive signal transduction leading to tumor cell growth, proliferation, invasion, and metastasis.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	KRAS inhibitor PF-07985045
Code name:	PF 07985045 PF 5045 PF-07985045 PF-5045 PF07985045 PF5045

pan-KRAS inhibitor PF-07985045

Search NCI's Drug Dictionary